Navigation Links
New "second-line" AIDS Drug Shows Promise in Trials

An experimental drug that researchers hope will cast a lifeline to HIV patients who have exhausted first-line treatment has shown early promise in long-awaited trials, The Lancet reports on Saturday.

Etravirine, also called TMC125, is designed as an alternative for patients who are resistant to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

An international consortium of doctors has been testing etravirine on NNRTI-resistant patients in two 48-week trials, the third and final phase of a long and complex process to assess new drugs for safety and effectiveness.

The volunteers in the DUET 1 and 2 trials are divided into two groups. Half receive etravrine and half a dummy, lookalike pill, a placebo.

In addition, all receive two standard anti-HIV drugs from a different treatment class, known as protease inhibitors, and also take selected NNRTIs.

The benchmark of success for helping patients with resistance problems is a "viral load" -- a count of the human immunodeficiency virus (HIV) which causes AIDS) -- to below 50 viruses per millilitre of blood.

At the 24-week point in the two trials, 56 and 62 percent of patients in the etravirine group had achieved this goal, The Lancet paper says. Among the "placebo" group, the rate was 39 and 44 percent.

Side effects were "mild or moderate" in severity, with generally little difference between the etravirine-takers and the placebo group.

Etravirine, made by a Belgian firm, Tibotec, has been closely followed by AIDS campaigners.

Antiretroviral drugs, as drugs to combat HIV are known, can save people with the AIDS virus, although they are not a cure.

But the longer a patient receives these drugs, the likelier it is that he or she will develop resistance problems as the virus mutates. In the case of NNRTIs, HIV can sidestep existing drugs with just a tiny mu tation in a single amino acid.

The treatment options narrow further if a patient is found to suffer bad side effects from these powerful molecules.

The hope for etravirine is that it will open up a new front against resistant virus and raise the genetic barrier to developing resistance.


'"/>




Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2017)... ... 19, 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, May ... respected lead singers in the rock industry would take his own life, but the extremely ... how mental illness played a role in the death of Chris Cornell . , ...
(Date:5/21/2017)... ... May 21, 2017 , ... For ... a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity issues ... is the third book from a recent series of from this conference. ...
(Date:5/19/2017)... ... 19, 2017 , ... In a continuous effort to raise awareness of autism ... company that specializes in natural and organic latex mattresses, has announced that they will ... unique share their recent viral Facebook video receives, up to $10,000.00. ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... The Hill ... to families and entrepreneurs throughout the California Central Valley, is announcing a joint charity ... raising community support for a local kid’s camp event. , The Boys and Girls ...
(Date:5/19/2017)... ... , ... ML Billing, 2016 Billing Company of the Year , a ... group practices, is pleased to announce their 30th anniversary. Not only has ML Billing ... all aspects of full-service medical billing. This has allowed ML Billing to excel for ...
Breaking Medicine News(10 mins):
(Date:5/2/2017)...  George Clinical, a leading full-service CRO in the ... Oncology, a Memphis -based leader ... that George Clinical has acquired Vector Oncology,s Pharma Services (CRO) ... purpose of strengthening the ability of George Clinical ... throughout the Asia-Pacific , the ...
(Date:5/2/2017)... , May 2, 2017  Bayer and Project Apis ... from Healthy Hives 2020, a $1 million research effort to ... by the end of 2020. The grant ... Rueppell , University of North Carolina at Greensboro, who will ... bees; Dr. Edmund Stark , Michigan ...
(Date:4/28/2017)... 28, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... for its fiscal second quarter ended March 31, ... The company,s results and updated guidance reflect the ... which was completed on February 14, 2017.  ... earnings of $0.51 per diluted share compared to ...
Breaking Medicine Technology: